Dilip Surana led Microlabs Limited Wins peoples heart, voted as Best Company to work for at Pharma Leaders 2016 annual power brand Awards.

Dilip Surana led Microlabs Limited Wins peoples heart, voted as Best Company to work for at Pharma Leaders 2016 annual power brand Awards.

Microlabs Limited voted by the jury members of the Network 7 Media Group’s annual pharmaceutical power brand awards in the category of Best Company to work for under the selection process of strong & robust HR policy aimed at building a world-class community of pharma professionals.

Microlabs received top recognition when the visionary CMD of Microlabs  Dilip Surana received the coveted award at the glittering annual award ceremony of Pharma Leaders Power Brand awards considered to be most credible & prestigious. The Trophy & Citations was received from the hands of Dr. Mukesh Batra, Chairman, Dr Batras & satya brahma, chairman & editor-in-chief, pharma leaders group where more than 400 industry leaders were present on friday, 23rd december 2016 at hotel sahara star.The set of 40 awards ware conferred to the top leaders & companies. Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications

DILIP-SURANA-_MICRO-LABS

With more than 9000 dedicated employees, 20 marketing divisions, 14 oral formulation plants with a strong R & D facility, the institution of Microlabs’s landmark & inspiring “Micro’s Performance Award”has been very exemplary. Indeed the employees continue to work as a one family & one team making Microlabs as India’s most respected pharma company with a formidable domestic marketing & strong export house. The growth of Microlabs has also been consistent over the last few years  & with among the top 10 companies like Cipla with  (20%), Mankind (21%), Alkem (28%), Macleods (30%), Lupin (24%) and Aristo (38%) grew faster &  Glenmark with  (26%), Micro labs (20%) and IPCA (27%) thus outpaced the market. Today Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations.

Ranking 14th among prescriptions (as per SMSRC May 16′ )and 19th in sales (as per AWACS MAT May’16) , Micro’s brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management.The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Environmental Protection & Social Initiatives with significant contributions in the areas of education and health. Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2020.

The Jury Members strongly believes that Dilip Surana’s visionary leadership integrates the task orientation style and people orientation style of leadership in a qualitatively new level of performance. The Company has made people perform tasks because they are happy to do them as they are inspired by the vision of building a successful healthcare empire. Under Mr. Dilip Surana’s visionary leadership,  the entire workforce showed exceptional results and made them perform beyond their imagined limitations. They are  happy not only because their leader is the best but because they have become their best selves because of their leader. The strong 9000 employees bear testimony of Company’s vision that  “people are the main priority at our establishment. Company’s people are essential to Company’s success. Company’s focus on building their capabilities, and aim to support and empower them to be the best they can be. You have attracted and retained the most talented people by investing in training, development, support, and learning opportunities. You rightfully realize that all the technologies and facilities amount to nothing in the hands of an unskilled employee. This reason alone motivates you to provide the best of opportunities and work conditions to Company’s dedicated members. As a progressive healthcare company, helping Company’s employees stay safe, healthy and productive is a priority.

Nation’s top healthcare leaders, pharma experts, policy makers, renowned doctors, social activists, bureaucrats & professionals of the Indian pharmaceutical & healthcare leaders assembled to witness the 9th annual pharmaceutical leadership summit & pharma Leaders business leadership awards 2016 organised by Network 7 Media Group’s Pharmaleaders, asia’s most analytical news media in healthcare communications. The theme of the Summit India@70, was presented by Annaswamy Vaidheesh, Managing Director – India & Vice President South Asia, GSK Pharmaceuticals India. Mr. Krishnakumar Subramaniam, Vice President, Business Development, India, Africa & Middle East, Glenmark Pharmaceuticals Ltd gave an opening Address & moderated the summit analyzing the speakers viewpoint.Satya Brahma,Chairman & Editor-In-Chief – Pharma Leaders Group in his opening address said “the change of guard in America with Donald Trump becoming US president, the impact of healthcare/pharma business will have a significant impact as Trump win might mean opportunities for Indian pharma.Trump had proposed to lift entry barriers for drug makers that offer safe, reliable and cheaper products. India contributes to nearly a third of all drugs sold in the US and this is unlikely to change for now, given the thrust of both Democratic and Republican parties on affordable health care. The US market will, however, continue to see pricing pressure as a result of consolidation of hospitals and insurance companies”. Increasing focus on Patients safety & concerns by hospitals & pharma companies will be key to healthcare innovations said Satya Brahma. The other notable speakers included Mr.Rajendra Pratap Gupta, Policy Maker, Researcher, & advisor to  Minister of Health & Family Welfare , Govt. of India addressed on “Digital Healthcare Innovations – Challenges & Opportunities”. The focus on healthcare delivery was evident as Health care in rural India– How technology can be leveraged for improving health care in Rural India was presented by Mayank Handhi, Social Activist in a interactive debate with Satya Brahma of Pharma Leaders. Dr. Manoj Khanna, Founder and Chairman, Enhance Clinics, Globally renowned Hair Transplant & Cosmetic Surgeon spoke on “Cosmetic Surgery Industry in India – Achi Din kya Aayenge?”. Vipin Pathak, Co- Founder & CEO, Care 24 addressed on Elder Care: Changing landscape, India and global. The highlight of the Summit at Pharma Leaders 2016 debate was on panel discussion moderated by Satya Brahma where top minds of the medical profession & healthcare addressed on “Is healthcare a commodity or a basic human need?”. The esteemed members of the panel discussion were Dr. Kishore Kumar, Consultant Neonatologist, Chairman,Cloudnine Hospital,Dr. Sudhansu Bhattacharyya, Head of Department of Cardiac Thoracic Surgery,  Bombay Hospital,Dr. Mudit Saxena, Group CEO Care Hospitals, Anand Garg, Former Chief Executive Officer, Seven Hills Health,Dr. Manoj Khanna, Chairman, Enhance Clinics,Dr. Debraj Shome, facial plastic surgeon and director, The Esthetic Clinics,Chandrashekhar Pandey – Founder and COO at Smile Merchants,Dr. Mannan Gandhi, Founder, The Integral Ayurveda,Rushi Trivedi – Founding Director & CEO at Smile Merchants

India’s Top 10 Powerful Influential Pharma Leaders 2016 List

India’s Top 10 Powerful Influential Pharma Leaders 2016 List

Prof Ramesh Mishra*

Pricing, Regulatory Hurdles & OTC Market remain the key focus at Pharma Leaders 2016 Research Report. Dilip Shanghvi, Pankaj  Patel, Samprada Singh, R.C.Juneja,Dilip Surana  are among top 10 Powerful Indian Pharma Leaders 2016

pl-super

Indian Pharmaceutical Industry has evolved as a dominant & powerful sector since india’s seventy years of independence & yet the industry remains largely fragmented with top 100 players in complete command of dominance. Today these top 100 companies have more than 80 % of the market share out of which majority players are domestic companies. MNC’s in india has grown significantly but their growth of late has been outpaced by the aggressive Indian companies. Pharma Leaders, India’s first media to interview more than 500 leaders of the pharmaceutical industry has brought out this special report titled “India’s Top 10 Powerful Pharma Leaders 2016” based on a credible research inputs followed by interviewing & interacting with all the stakeholders of the pharmaceutical industry. The key findings of the report other than the selection of the top 10 Leaders are as the following.

1

3

4

g-m2m_pharma_web healthcare-august-2015 healthcare-nov-2015 jpg pharmaceuticals-nov-2015

Using comprehensive interview, survey, and observational data from 100 successful Pharma Leaders using the competitive market analysis, the researchers found that our findings on the top 10 influential Powerful Pharma Leaders of 2016 — defined as aggressiveness, assertiveness, and confidence — were also able to “excel in tough conditions considered very risky”.

Key Findings:

  • Indian Players are likely to dominate the market till 2025
  • Top 100 Domestic Players may join hands together through co-marketing, R&D & brand acquisitions.
  • Top privately held companies will go for public (IPO) in next 2 years, till 2018
  • Top Brands will be up for grabs with premium
  • Generics will be the key drivers for growth
  • Top 100 companies will set up manufacturing facilities to fuel growth engines.
  • Second generation Leaders will take over the Leadership Mantles.
  • OTC segments will be the part of top 40 companies out of 100.
  • Field Force of top 30 Companies will double by 2018.
  • Exports will be the key focus.

India’s Top 10 Powerful Pharma Leaders 2016

Overview

There are many organizations who are involved in rankings based purely on turnovers or profits or purely on financial background. While Pharma Leaders research desk purely respects the mechanism of selection process & the judging criteria, we have given considerable emphasis on the trust & branding factors & the credible face of the leadership steering the company’s growth engine & putting patients first. In this feature survey, we have only taken the Indian companies & not included the MNC’s as the scope of the study research involved included the role of visionary leadership, team buildings, brand buildings, CSR & Indian perspective of looking leadership. Network 7 Media Group, the research wing of Pharma Leaders undertook the responsibilities of finding the top 10 Powerful Pharma Leaders of 2016.

The primary objective that our experts looked at is Brand Equity & Leadership Dominance. Indian pharma market is dominated by a strong patronage of brands by the different stakeholders; the research paper looked into great details as how the person concerned has been able to influence the society & industry at large. Corporate Social Responsibilities (CSR) also was one of the top focus while determining the leadership role of the top 10 influential Pharma Leaders of 2016.

Selection Process & Methodology 

 Unlike other organizations, Pharma Leaders being a media house relied purely on the external patronage & opinions of the key stakeholders on determining the top 10 Leaders.The sample size of the analysis included all 29 states & 7 Union territories, both urban & rural areas on a pan india basis. More than 5000 opinion makers were consulted which included the followings.

  • Contemporary Peers
  • Past Leadership
  • Distribution Agents
  • Pharmacists
  • Doctors
  • Policy Makers
  • Govt Agencies
  • NGO’s
  • Image Consultants
  • Medical Representatives
  • Consultants
  • Market Research Analysts

……………………………………………………………………………………………………………

The Top 10 List

  1. Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd
  2. Desh Bandhu Gupta, Chairman, Lupin Limited
  3. Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd
  4. Y.K. Hamied,Non-Executive Chairman,Cipla Ltd
  5. Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila
  6. Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd
  7. Samprada Singh, Chairman Emeritus,Alkem Labs Ltd
  8. Dilip Surana, CMD, Microlabs Ltd
  9. R.C.Juneja, Chairman, Mankind Pharma Ltd
  10. Habil. F.Khorakiwal, Chairman, WockhardtLtd

dilp

Mr. Dilip Shanghvi,MD,Sun Pharmaceutical Industries Ltd

The current market capitalisation of Sun Pharma  stands at Rs 184,441.59crore.

Mr. Dilip Shantilal Shanghvi founded Sun Pharmaceutical Industries Limited in 1982 and served as its Managing Director since May 29, 2012. Mr. Shanghvi served as the Chairman and Managing Director of Sun Pharmaceutical Industries, Inc. He has been the Chairman and Managing Director of Sun Pharma Advanced Research Company Limited since March 1, 2012. He has wide extensive industrial experience in the Pharmaceutical industry. He has been the Chairman of Taro Pharmaceutical Industries Ltd., since July 18, 2013. Mr. Shanghvi has been the Chairman of Caraco Pharmaceutical Laboratories Ltd. since 1997. Mr. Shanghvi served as the Chairman of the Board of Sun Pharmaceutical Industries Ltd until May 28, 2012. since 1999. He served as the Chairman of the Board of Taro Pharmaceutical Industries Ltd. from September 20, 2010 to April 18, 2012. He has been a Director of Sun Pharma Advanced Research Company Limited since March 1, 2006. He serves as a Director at Sun Speciality Chemicals Pvt. Ltd., Sun Resins & Polymers Pvt. Ltd., Sun Fastfin Services Pvt. Ltd., Sun Petrochemicals Private Limited, SPARC Bio-Research Private Limited, Sun Pharma Global Inc., British Virgin Island, Sun Pharma De Mexico SA DE CV, SPIL De Mexico SA DE CV and Shantilal Shanghvi Foundation. He serves as its Promoter Executive Director of Sun Pharmaceutical Industries Ltd .He served as a Director of Taro Pharmaceutical Industries Ltd. until April 18, 2012. Mr. Shanghvi is graduate in commerce from Kolkata University.

Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company, manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, such as psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental, and nutritionals. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India


logo

Dr Desh Bandhu Gupta, Chairman, Lupin Limited

The current market capitalisation of Lupin stands at Rs 67,437.26 crore.

Dr. Desh Bandhu Gupta is Chairman at Lupin Ltd. He is on the Board of Directors at Zyma Laboratories Ltd., Rahas Investments Ltd., Visiomed Investments Pvt. Ltd., Lupin Holdings Pvt. Ltd., Lupin Investments Pvt Ltd., Lupin International Pvt Ltd., Polynova Industries Ltd., Lupin Properties Ltd., Novamed Investments Pvt. Ltd., and Synchem Investments Pvt. Ltd.Mr. Gupta was previously employed as an Associate Professor by Birla Institute of Technology & Science. In 1968 at 30 years of age, Desh Bandhu Gupta started off with was a very ambitious dream of manufacturing drugs of national priority. The aim was to fight life threatening diseases with a business capital of 5000 Indian Rupees that he borrowed from his wife. He started his working career as Associate Professor at Birla Institute of Sciences and Technology, but never seemed satisfied with his contributions to the country and society. With an initial investment coming his way in the form of loan from the Central Bank, he set up the manufacturing unit in Mumbai and attained this uphill task he had set of first year; Sales target of 5 lakh Indian Rupees.

Lupin Limited, a pharmaceutical company, develops, manufactures, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiology, central nervous system (CNS), diabetes, anti-asthma, gastro- intestinal, COPD, and gynecology; and APIs for use in therapeutic areas of cephalosporins, cardiovascular, and anti-TB. The company also develops drug delivery technologies; and biosimilars for various therapeutic indications, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women’s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.


236139-satish1

Mr. Kallam Satish Reddy,Chairman,Dr. Reddy’s Laboratories Ltd

The current market capitalisation of Dr. Reddy’s Labs stands at Rs 54,502.30crore.

Mr. Kallam Satish Reddy, B.Tech., M.S., serves as a Member at Management Council at Dr. Reddy’s Laboratories Ltd. Mr. Reddy served as the Managing Director of Dr. Reddy’s Laboratories Ltd. and has been its Chairman since May 13, 2014. Mr. Reddy served as Executive Director in charge of the manufacturing operations of active pharmaceutical ingredients and formulations, research and development activities and new product development at Dr. Reddy’s Laboratories Ltd. since 1993 and served as its Chief Operating Officer. He served as Vice Chairman of Dr. Reddy’s Laboratories Ltd. from March 30, 2013 to May 13, 2014. He has been a Whole Time Director at Dr. Reddy’s Laboratories Ltd. since January 18, 1993, Director of Diana Hotels Limited as well as certain of Dr. Reddys Laboratories Ltd.’s subsidiaries. and also served as Director at Dr. Reddy’s Laboratories Ltd. He served as Director of Cheminor, and is a member of the Indian Institute of Chemical Engineers. Mr. Reddy has a Master of Science degree in Medicinal Chemistry from Purdue University in 1990 and a Bachelor of Technology degree in Chemical Engineering from Osmania University in 1988.

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs) for dermatology and neurology therapeutic areas. It also engages in the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as metabolic disorders, and pain and inflammation; and has a portfolio of in-licensed patented dermatology products. As of March 31, 2016, this segment had 19 active products in development programs pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. It has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreements with Merck Serono and Amgen. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

dsc-0013-edited-274x186

Dr. Y.K. Hamied,Non-Executive Chairman,Cipla Ltd

The current market capitalisation stands at Rs 48,590.40crore.

Dr. Yusuf Khwaja Hamied, also known as YK, served Managing Director of Cipla Limited from August 1, 2008 to March 31, 2013. Dr. Hamied joined the Cipla Limited as an officer-in-charge of research and development in 1960. He is well-respected for his vast and varied experience of 48 years not only in India but also internationally. He has done research work under Lord Todd FCS, a Nobel Laureate. He is a highly qualified and Eminent Chemist. He has been the Chairman at Cipla Limited since April 1, 2013. He serves as Non-Executive Non Independent Director at Cipla Limited. He obtained a Doctorate in chemistry from Cambridge University.

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including companion, equine, livestock, poultry, swine, and aqua products. In addition, it offers inhaled medication and devices comprising dry powder inhalers, metered-dose inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices; and personal products. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, China, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.


pankaj-patel

Mr.Pankaj R. Patel,Chairman & Managing Director,Zydus Cadila

The current market capitalisation of Cadila Healthcare stands at Rs 40,248.44 crore.

Mr. Pankaj R. Patel, M.Pharm, serves as the Chairman of Cadila Healthcare Limited and has been its Managing Director since September 1, 2006. Mr. Patel serves as the Chairman and Managing Director of Zydus Animal Health Limited, a subsidiary of Cadila Healthcare Limited and he is the guiding force behind its fast tracked growth. He has been Senior Vice President at Federation of Indian Chambers of Commerce and Industry since December 2015. He serves as the Regional Representative to the South East Asia Region of WHO. He over 35 years of professional experience and spearheads the affairs of Zydus Cadila. He served as the Non Executive Chairman of Zydus Wellness Limited from August 2009 to July 14, 2014. He serves as a Non-Executive Independent Director of Nirma Limited. He has been an Independent Non-Executive Director of Torrent Power Limited since September 29, 2006 and Cadila Healthcare Limited since August 15, 1995. He served as a Non Executive Director of Cipla Limited from March 5, 2008 to September 2014. He served as a Director of Zydus Wellness Limited from April 27, 2009 to July 14, 2014. He served as a Director of Dialforhealth India Limited, Zydus Pharmaceuticals Limited, BAAP Diagnostics Limited, Zydus Technologies Limited, Vadilal Chemicals Limited and Kafnavati Club Limited. He served as a Director of Onconova Therapeutics, Inc. He served as a Director at Gujarat Themis Biosyn Ltd. from January 15, 1992 to October 25, 2008. He served as Additional Director of Nirma Limited since October 28, 2006. He has been the President of Gujarat Chamber of Commerce & Industry since 2006. He is involved in many charitable activities including as a Trustee of Shri. B.V. Patel Pharmaceutical Education and Research Development Center in India. He is associated with various associations like Federation of Indian Chamber of Commerce & Industry, Indian Drug Manufacturers Association, Indian Pharmaceutical Alliance, Basic Chemicals, Pharmaceuticals and Cosmetics Export Promotion Council (CHEMEXIL) etc. He is actively involved in various institutions and serves on the advisory committees and academic councils of leading pharmaceutical colleges and management institutes. He has published over 50 research papers. For his innovative business practices, he was conferred with the award “Pharma Man of the Year” by the Federation of Indian Industry and Economists in 2004. The World Pharmaceutical Frontiers’ in their global raking of the most influent people in the filed of healthcare had featured Mr. Patel in their ‘First Pharma 40’ list. He is one of the most successful and highly respected Pharma entrepreneurs in India. He has a Masters in Pharmaceuticals and Pharmaceutical Technology. He is a Science graduate of Bombay University. He is a Law graduate from the Bombay University.

Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients and human formulations. The company offers branded formulations in the therapeutic areas of neurological, neutraceutical, pain management, gastro intestinal, respiratory, anti-infective, biological, cardiovascular, female healthcare, dermatology, and others. It also provides consumer wellness products, such as Sugar Free, a low calorie sugar substitute; EverYuth, a range of skincare products; and Nutralite, a cholesterol free table spread. In addition, the company is developing a pipeline of 20 biologics comprising 14 biosimilars and 6 novel biological products; and new drugs in cardio-metabolic disorder, inflammation, pain, and oncology therapeutic areas. Further, it provides animal healthcare products. Additionally, the company is developing vaccines that are designed to address infectious diseases, including next-generation influenza, measles-mumps-rubella-varicella, typhoid, DPT-HiB, hepatitis-B, hepatitis-A, hepatitis-E, Japanese encephalitis, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, HPV, and combination vaccines. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.


glenn-saldanha_0

Mr. Glenn Saldanha, CMD, Glenmark Pharmaceuticals Ltd

The current market capitalisation of Glenmark stands at Rs 26,152.76 crore.

Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Ltd. since 2001. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceuticals S.A. He has worked for Eli Lilly in the U.S and was a Management Consultant with Price Waterhouse Coopers. His Services have been used by Smithkline Beecham, Rhone Poulenc Rhorer, Astra, Merck and Johnson and Johnson, among others. He has 15 years of experience in Pharmaceutical Industry. He has been the Chairman of Glenmark Pharmaceuticals Ltd. since May 10, 2011. Mr. Saldanha served as Chairman of Glenmark Generics Ltd. He has been a Director of Glenmark Pharmaceuticals S.A. since 1998. He served as Independent Director of Talwalkars Better Value Fitness Ltd. since October 2009 until November 22, 2011. He was awarded the Watumall Foundation Award for overall excellence. Mr. Saldanha holds a B.Pharm. from Bombay University and an MBA from New York University’s Leonard N.Stern School of Business (US).

Glenmark Pharmaceuticals S.A operates as a pharmaceutical research and development company. It engages in clinical and non-clinical development of the group’s new chemical entity programs. The company’s products include Oglemilast, a PDE-4 inhibitor for asthma; GRC 8200, a DPP-4 inhibitor for diabetes; GBR 401, an anti-CD19 monoclonal antibody; CB-1 antagonist for obesity; and GBR 500, a therapeutic monoclonal antibody for chronic autoimmune disorders. The company has a strategic global collaboration with Sanofi. The company was founded in 2004 and is based in Neuchâtel, Switzerland. Glenmark Pharmaceuticals S.A operates as a subsidiary of Glenmark Pharmaceuticals, Ltd.


samprada

Mr. Samprada Singh, Chairman Emeritus,Alkem Labs Ltd

The current market capitalization of Alkem stands at Rs 21,927.62crore.

Mr. Samprada Singh founded Alkem Laboratories Limited in August 8, 1973 and has been its Chairman Emeritus since April 1, 2015. Mr. Singh served as the Chairman of Alkem Laboratories Ltd. Mr. Singh is one of the most respected and successful entrepreneurs of the Indian Pharmaceutical Industry. The growth of Alkem and the success of Mr. Singh is most amazing since Mr. Singh started this organization from scratch and through tremendous dynamism, vision and leadership has brought it to the top of the Indian Pharmaceutical Industry today. To Mr. Singh goes the major credit of seeing Alkem through its various stages of progress from the beginning, till today, when Alkem is a name to reckon with in the Indian Pharmaceutical Industry. In 1953, Mr. Singh made a small beginning as a Retail Chemist. In 1960, he started a business of Pharmaceutical distribution in Patna under the banner of ‘Magadh Pharma’. Due to his sincerity, hard work and affable nature, Mr. Singh was able to acquire the distributorship of several renowned multinationals and soon, successfully built up a sound distribution network in the eastern region of India. Realizing the limitations of expanding in the distribution business, in the year 1972, Mr. Singh became the founder Director of a Bombay based Pharmaceutical company. Mr. Singh selected healthcare and pharmaceuticals as his focus area as an entrepreneur. From the very early days of Alkem Laboratories Ltd., Mr. Singh always emphasized the need for excellence in products, personnel, quality and service. He has been a Non Executive Director of Alkem Laboratories Limited since August 08, 1973. In the year 2004, Mr. Singh was honoured with the prestigious “Life Time Contribution Award” by the Express Pharma Excellence Awards, which is reckoned by many as the Oscar of the Indian Pharmaceutical Industry. In June 2002, Mr. Singh received yet another award. The ‘Medicine Update Lifetime Achievement – Health Care Award’ went onto honour his achievement in the pharmaceutical industry as one of it’s most successful entrepreneurs. In October 2000, Mr. Singh was conferred upon with the ‘Life Time Achievement Award’ by Pharma Business and Technology, one of the most distinguished and respected entrepreneurs of the Indian Pharmaceutical industry. During Mr. Singh four years as an undergraduate, Mr. Singh exhibited his dynamism through various student activities. Mr. Singh entered Gaya College, Patna University in 1946 to specialize in Commerce. He received a B.Com. Degree from Patna University in 1950. Mr. Singh holds a post graduate degree in Political Science.

Alkem Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells pharmaceutical and neutraceutical products. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and neutraceuticals in acute and chronic therapeutic areas, such as anti-infective, gastro-intestinal, pain and analgesics, vitamins/minerals/nutrients, cardiac and diabetology, gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants. It offers its products to various hospitals, government institutions, and medical institutions through a network of 7,000 stockiest in India and internationally. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India.


dilip-anand-surana_416x416

Mr. Dilip Surana, CMD, Microlabs Ltd

Privately held Company

Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs Limited) joined the family business in 1985 at a young age of 21 years, and  rapidly absorbed the nuances of Corporate Management that grew the company rapidly into a global pharmaceutical enterprise specializing in life saving medicines. His early years in industry were marked by distinguished accomplishments and thus steering Micro Labs among the top ranking companies in the pharma sector. The AWACS ranking for the company has improved from over 100 in 1985 to 18 as on 2014.  Under his leadership, the company established world-class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery. He instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities. He pioneered the concept of specialty – wise focused divisions in the Indian Pharmaceutical Industry and established various divisions that cater to special therapeutic segments in chronic disease management. He is a regular participant in various international seminars and summits relating to Pharma industry. He is instrumental in inducting Senior Pharma veterans in the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the Year’ 2013 and ‘Entrepreneur of the year’ 2014.

Micro Labs Ltd. manufactures pharmaceutical products. It offers products ranging from oral solids and liquids, topicals to injectables in pediatric, gynecology, ophthalmology, gastro, orthopedic, nephrology, neuro psychiatry, dermatology, diabetology, general surgery, ENT, dental, neurology, cardio diabetic, dyslipidemias, hypertension, metabolic syndrome, arrhythmias, and veterinary areas. The company markets branded generics through own and outsourced distribution networks in India and internationally. Micro Labs Ltd. was founded in 1973 and is based in Bengaluru, India. It has subsidiaries and representative offices in the United Kingdom, the Russian Federation, Vietnam, Ukraine, and Mexico. The company has manufacturing plants in Hosur, Bengaluru, Pondicherry, Goa, Baddi, and Sikkim, India; and the United Kingdom, Canada, and South Africa.


Corporate Portrait Photography for Mankind Pharma Group of all the Directors, Chairman, Managing Director. Pictures were shot at ManKind Pharma Corporate office in Delhi in the month of December 2011 CEO Portrait Shoot by Guru Dutt & Sharmila representing Guru Dutt Phtography/ Prashanti Photography.

Privately held Company

Mr R. C. Juneja, the founder of Mankind Group, is one of the most reputed business leaders in the pharmaceutical industry. He laid the foundation stone of Mankind Pharma in 1986, and the company became a legal entity in 1991. Mankind Group earned its reputation as a fully integrated pharmaceutical company in 1995. In 2011, Mr. Juneja was presented with the ‘India Business Icon (Pharma) Award’ by Network 18.He firmly believes that honesty and transparency go hand-in-hand with business acumen. He also shares his life experiences with the youth and encourages them to come forward and take up new challenges and responsibilities. He revolutionized the Indian pharmaceutical market by inspiring others to follow the trend of providing quality products at an economical price.

Mankind Pharma Limited manufactures pharmaceutical products for antibiotic, antifungal, NSAIDs, gastrointestinal, anthelmintic, cardiovascular, dermal, erectile dysfunction, and other categories. It also offers contraceptive products, over-the-counter medicines, pregnancy detection cards, artificial sweeteners, and other products; and nutritional supplements, cosmetics, anti-infective tablets, anti-diabetic tablets, proton pump inhibitors, anti-allergic tablets, emergency contraceptives, anti-emetic, and other products. In addition, the company provides active pharmaceutical ingredients for various therapeutic areas, such as cardiology, respiratory, neurology, gastroenterology, diabetology, dermatology, ophthalmology, gynecology, and others. It sells its products through a network of stockists, CFAs and CSAs, chemists and medical stores, and doctors. Mankind Pharma Limited was incorporated in 1991 and is headquartered in New Delhi, India. It has operations in Asia, Africa, South-East Asia, and Gulf countries.


khorakiwala-h10

Mr. Habil. F.Khorakiwal, Chairman, WockhardtLtd

The current market capitalisation of Wockhardt stands at Rs 10,060.98crore

Dr. Habil F. Khorakiwala founded Wockhardt Ltd. in 1967 and serves as its Executive Chairman. Dr. Khorakiwala has bee Group Chief Executive Officer at Wockhardt Ltd. since 1967. Dr. Khorakiwala served as the Managing Director of Wockhardt Ltd. until April 2009. Dr. Khorakiwala serves as the Chairman at Wockhardt USA, Inc., and Wockhardt Hospitals Ltd. He serves as the Chairman of Khorakiwala Holdings and Investments Private Limited. He serves as Chairman of Wockhardt Bio AG. He serves as Director of Dartmour Holdings Private Limited. He has been a Director at Wockhardt Hospitals Limited since August 28, 1991. He serves as a Director of Wockhardt Bio AG, Wockhardt Europe Limited and CP Pharmaceuticals Limited. He is an Ex-President of Indian Pharmaceutical Alliance (IPA). He served as a Director of SOFTBPO Global Services Ltd. since August 1, 2006. Dr. Khorakiwala served as an Independent Director of IDream Film Infrastructure Company Ltd from October 26, 2005 to January 28, 2014. He serves as a Vice-President of FICCI and a member of the National Manufacturing Competitiveness Council. Dr. Khorakiwala was the recipient of the Ernst & Young `Entrepreneur of the Year’ Award in 2004 in the category of Healthcare and Life Sciences. He holds Bachelor’s Degree in Pharmacy from Purdue University. Dr. Khorakiwala holds an Master Degree in Pharmaceutical Science from the Purdue University, USA and is an alumnus of the Harvard Business School, USA.

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines in India, the United States, Europe, and other countries. It provides pharmaceutical products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. It develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.

The Author Prof Mishra is Executive Editor of Pharma Leaders.

Top Cardiologist Dr. Kaushal Pandey honored at Pharma Leaders Super Brand Awards 2015

Top Cardiologist Dr. Kaushal Pandey honored at Pharma Leaders Super Brand Awards 2015

Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015 Award Conferred to Dr. Kaushal Pandey, Cardio Thoracic and Vascular Surgeon

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognizing the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one platform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Hinduja Hospital CEO Mr. Gautam Khanna debated on the challenges of Indian Healthcare Insurance while Padma Sree Prof Dr. Shashank Joshi addressed on Brand India.

 

 

 

Dr.Kaushal Pandey made a passionate presentation on World Class Individuals : mediocre institutions: & failing medical education. The Award Winning Cardiac Surgeon stressed the need for qualatative improvement of healthcare services in the country to make healthcare accessable to the indian masses.

Expressing concern over the falling standard of education in both public and private medical colleges affecting patient care and healthcare quality in the country, Dr Kaushal Pandey, one of the renowned consultant cardiovascular surgeons associated with P. D. Hinduja National Hospital & Research Center, has stressed on the need for a major overhaul of the medical education system to produce quality doctors to ensure high quality healthcare.

“India produces around 50,000 MBBS doctors annually as compared to 18,000 doctors in USA but training of our doctors are not up to the mark as compared to doctors abroad. In India, the MBBS students do not get enough exposure to clinical materials and surgical procedures during the course to become well trained doctors, and there are a chunk of students who don’t have aptitude to become a doctor but they join a medical college just because their parents manage to secure seats for them in the medical college. Such doctors are risk for patients. The quality of the faculty in medical colleges is also not up to the mark,” said Dr. Pandey.

There is no legal compulsion for doctors to undergo re-training in the country. There is no system to audit the doctors on any quality of care measures which provide them freedom to do whatever they want after the basic qualification is secured. In absence of scrutinisation and monitoring to ensure accountability of doctors in public hospitals in both urban and rural areas, absenteeism among doctors has become common sight leaving scores of needy patients in lurch. It is not the case with private hospitals which have a stringent monitoring system to make doctors accountable to patient care, he said.

“If the government is really worried about people’s health and if the country is to stay competitive globally, it has to exercise its authority to introduce reform to medical entrance test so that students having aptitude to become a doctor get admission to medical colleges. Commercialisation of medical education flooding the market with poor quality doctors should be stopped at the earliest without any loss. The exorbitant capitation fees charged by private medical institutes from students should be regulated to make education affordable for deserving and needy students and steps need to be taken to overhaul the regulatory framework pertaining to quality of instruction, faculty development and curbing private practice,” noted cardiac surgeon said.

In order to overcome the shortage of quality faculty members in public medical colleges, the government needs to revive the old honourary system attached to healthcare in the country where talented, renowned doctors used to conduct classes for students in government medical colleges for two-three days imparting them theoretical and practical insight into the course. They used to charge nominal fees for it, he added.

He said that the government also needs to make integrated protocol-based diagnoses and treatment systems into the teaching programme for medical students and make them take a test after a certain period to ensure their skills updation and encourage use of technology with applications like clinical decision support systems to improve the quality of healthcare delivery.

Geographical location and infrastructure facilities should be taken into account in starting an AIIMS like institutes in the country by the government to ensure maximum optimisation of such facilities, he concluded.

Of the 4,000-odd multi-crore infrastructure projects in the country, only nine (0.21%) – with a total investment of Rs 938 crore – are in the health sector, according to data published by the finance ministry.The public-private partnership (PPP) projects range from diagnostic centres to super-specialty hospitals. Investments in the health sector are far lower than those in the transport and energy sectors. The lack of health facilities in India’s villages reflects the low investment.About 20% (35,389) of the 182,709 public health facilities in rural areas do not have their own premises, according to a 2014 rural health statistics report. There was a shortage of 6,700 (23%) public health centres and 2,350 (33%) community health centres as of March 31, 2014, according to data tabled in the Rajya Sabha.Government spending on health has come down from Rs 37,000 crore ($5.5 billion) in 2013-14 to Rs 30,000 crore ($4.5 billion) in 2014-15. India spent $69 per capita on health in 2013, the lowest among developing nations. Even poorer economies like Indonesia and Mexico did better, according to data published by the Organization for Economic Co-operation and Development


Dr.Kaushal Pandey received the prestigious award title “Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015from the hands of the iconic music composer Louis Banks who has often  been referred to as the Godfather of Indian Jazz  in the presence of Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders Group.

Dr.Kaushal Pandey is one of country’s top cardiologist & is much respected & admired in the healthcare profession.Dr.Kaushal Pandey specializes in Cardiovascular & Thoracic Surgery & his area of Interest are in Bilateral IMA and Radial Artery Grafts for CABG, LV Aneurysm and CABG in poor L V function,Bio Prosthetic Valve Replacement,Redo Valve and Redo CABG Surgery,Infective Endocarditis and infections in Cardiac Surgery & his Key Achievements include among many are winning  P. K. Sen Memorial Oration award at Indian Association of Cardiovascular thoracic Surgeons Conference, 2006, Dr. K. N. Dastur Memorial Oration award at IACTS CON 2012. Dr.Kaushal Pandey is credited with performing of over 14500 open-heart surgery procedures in Mumbai since 1991,Over 50 major presentations and articles in national and international conferences and journals.In the year. Pharma Leaders crowned him as Incredible Medical Expert of the Decade in the year 2013 & Indian Affairs ( A Division of Network 7 Media Group) felicitated the accomplished cardiac surgeon as India’s Most Promising Face in Cardiology at the 3rd Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2015.


Microlab’s CARIPILL receives Emerging Brand of the Year at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015

Microlab’s CARIPILL receives Emerging Brand of the Year at the 8th Annual Pharmaceutical Leadership Summit & Pharma leaders Business Leadership Awards 2015

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognising the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one plattform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Microlab’s CARIPILL received the top recognition at the Pharma Leaders Power Brand Awards. Mr. Ashok Jain, Executive Director of Microlabs received the Trophy & Certificate of Excellence from Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred to top achievers of the country & urged the industry to provide affordable medicines to the common masses in india.

 Satya Brahma, founder of Pharmaleaders in the opening address lambasted the union government for the faulty healthcare reforms & policy paralysis. In a scathing attack to the policy makers, Satya said “the Healthcare Challenges in India at present are of different dimensions & more of cleaning the system at the helm who are responsible for formulating laws, rules & regulations. While we can’t ignore the concerns of the pharma companies facing complex issues in regulatory legal hurdles in IPR challenges, pricing &other issues related to patent regime. Pharmaleaders believe that the evolving global and domestic market dynamics are likely to result in significant opportunities and challenges for pharma companies operating in India, both Indian companies as well as Indian affiliates of MNC companies. Some key issue areas are already starting to capture the attention of leadership teams within the industry.


Bengaluru-based Micro Labs, a fully integrated pharma company recently launched Caripill, which helps to increase the platelet count in patients suffering from dengue.  Approved by the scientific and regulatory authority, the pill is made from Carica Papaya leaf extract and reportedly does not have any side-effects.  Being a product of extensive R&D and clinical trials conducted by Micro Labs, the pill has proved its safety and efficacy in about one lakh patients across India, claims a company release.

MicrolabsCaripill Syrup Pack shotCaripill Tablet Pack shot
Speaking about Caripill, Dr AC Gowda Fortis Hospital, Bangalore and Principal Investigator, Clinical Trial for Caripill said, “The encouraging results on the dengue patients has shown the immense potential of what Caripill is capable of, that eventually can be administered on patients with other life-threatening diseases, like leukaemia among others, which requires intense chemotherapy leading to loss of platelets.” He added, “After an extensive research across two years conducting clinical trials on 250 patients, we have seen positive results with a dramatic decrease in the haemorrhage condition, besides, none of the patients who are administered the drug have had to undergo blood transfusion so far.”

Caripill costs Rs 25 per tablet with the dosage of administering one pill (1100 mg) three times a day, for five days.

No specific treatment was available for treating dengue, except for some paracetamol tablets (mostly Dolo 650 by Micro Labs) to reduce the fever/ temperature. However, immediately post the fever reduces, the platelets count on blood starts falling leading to serious health consequences. Despite considerable efforts to control the mosquito population, dengue fever has emerged, spread and established itself rapidly. Looking into the limited current modalities of treatment and its affordability to a fewer sections of population, Caripill can be of considerable use.

Ashok Jain, Executive Director, Micro Labs, stated, “Over four decades, we have been successful in manufacturing oral solids, liquids, topical and injectable medication for patients across verticals – diabetology, cardiology, ophthalmology, dermatology, pain/analgesics, etc.  Today, I would like to congratulate our team at Micro Labs for making a remarkable breakthrough in treating moderate to severe dengue cases with the newly introduced Caripill that comes at an affordable cost.”

Dr Nagabhushan KH, VP-Medical Services, Micro Labs, stated, “At present, the popular treatment for dengue is by oral consumption of juice crudely extracted from the non-standardised and unhygienic papaya leaves with no clear dosage specified, that could have a detrimental impact on sufferers. Our new Caripill, has received positive feedback from doctors treating patients with dengue and are confident the usage of the pill can be further extended to treating patients with other life-threatening disorders that require restoration of blood platelets.”  He further added, “The rising number of dengue cases among children, has driven us to introduce a paediatric Caripill syrup for easy consumption and plan to launch it soon.”

Caripill has been made available in all major pharmacies across India.

Reportedly it doesn’t have any side effects. According to the clinical trials, Caripill has shown positive results. A plus point is, none of them had to undergo blood transfusion. And henceforth, they are thinking of utilizing in patients with leukemia who have thrombocytopenia post chemotherapy, in future. As far as I have come across, it costs 25/- per tablet. Presently if we see the limited modalities of treatment, and the fact that it can be afforded only by fewer strata of the society, I think yes, Caripill can be worth it. Yes, caripill has some questions before it is fully accepted as platelet booster. However, given the scenario of dengue where platelet transfusion is the only option for severe depletion, caripill is a worth trying drug. Totally chemical free, I do recommend its usage and have found it to be useful. It defenitely reduced the need for platelet transfusions in some but not in all., to me, it is a worth trying drug but make sure you take it only after your doctor suggests it.Yes Micro Labs has introduced Caripill which is tablet containing leaf extract of papaya (Carica Papaya Leaf extract). It is available in market and many doctors are prescribing & have found it to be useful. However, it is advised to be taken after discussing with your doctor. One should know when to start taking Caripill (ie at what level of platelet count) and doctors are best to judge. You can contact Micro Labs @ +919845855122 by sending a message with your details and a request to call back. Caripill Cell will call back with more information.


Established in 1973, Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations.
In  Indian Pharmaceutical Market, Micro labs is ranked 15th among prescriptions (as per SMSRC Jul’15) and 19th in sales (as per AWACS MAT Sep’ 15).The brand portfolio of Micro Labs includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management.Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2017.

Other accomplishments include:

  • Brand Dolo won ‘Best Managed Brand Award’ awarded by the Institute of Pharmaceutical Healthcare Management & Research’s conference in 2010
  • Dolo 650 was awarded as ‘Brand of the Year 2013’ at 6th Annual Pharmaceutical Leadership Summit 2013
  • Dolo 650 also won the Brand of the Year 2014 GOLD award and Amlong won Brand of the Year 2014 BRONZE Award at AWACS Marketing Excellence Awards 2014
  • Dilip Surana has been been honoured time and again with prestigious awards such as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the Great Son of Karnataka’ by Governor of Karnataka his Excellency HR Bhardwaj in 2011
  • Dilip Surana has been bestowed with the title of ‘Most Dynamic Entrepreneur of the Year’ at 4th Annual India Leadership Conclave and Indian Affairs Business Leadership Awards 2013. He was also honoured as‘Entrepreneur of the Year 2014’ in the following year.
  • Micro Labs has also introduced a lot many number of formulations for the 1st time in the country like Anxit, Dolo-650,Silybon,Ebast and Caripill
  • Various manufacturing facilities of Micro Labs have bagged Quality Excellence awards consistently year after year

Milestones:

  • 19 specialty divisions,with a wide product range and a dedicated field force of 4500 plus.
  • 14 World class manufacturing facilities approved by various agencies including US FDA, UK-MHRA, MCC-South Africa, Health Canada, WHO, TGA Australia & Medsafe-New Zealand, with 2000 qualified technical personnel
  • A vibrant presence in over 40 countries, exporting formulations in all major therapeutic segments
  • Three R&D centres with more than 250 experienced scientists
  • GDA foundation runs the Surana College and Surana PG centre in Bangalore and “Smt. Pyaribai Chunnilalji Surana Charitable trust runs Shree Parshwa Susheel Dham”, a magnificent Jain temple in Attibele, Bangalore

The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Social Initiatives with significant contributions in the areas of education and health.

Pharma Leaders Super Brand Awards Conferred to Nation’s Top Healthcare Leaders

Pharma Leaders Super Brand Awards Conferred to Nation’s Top Healthcare Leaders. Huzaifa Khorakiwala of Wockhardt, Varun Khanna of BD India, Emcure Pharma, Akumentis Healthcare,Koye Pharma, Bajaj Allianz,Abbott India among others shined at Pharma Leaders 8th Annual  Awards 2015

The 8th Annual Pharmaceutical Leadership Summit & Business Leadership Awards was successfully concluded at the financial capital of india in Mumbai at Hotel Hilton today where more than 300 top leaders of the healthcare industry had gathered to be the part of the historic debate on  “Pharma Leaders 2015, Brand India Winning”. Widely acclaimed in the healthcare industry as the pioneer in recognising the leaders of today & tomorrow, Pharma Leaders brought together veteran healthcare leaders under one plattform. The leadership Summit in the afternoon session debated crucial topics such as Healthcare Insurance, Medical Tourism, Challenges of Indian Pharma Industry. Hinduja Hospital CEO Mr. Gautam Khanna debated on the challenges of Indian Healthcare Insurance while Padma Sree Prof Dr. Shashank Joshi addressed on Brand India. 

Satya Brahma, founder of Pharmaleaders in the opening address lambasted the union government for the faulty healthcare reforms & policy paralysis. In a scathing attack to the policy makers, Satya said “the Healthcare Challenges in India at present are of different dimensions & more of cleaning the system at the helm who are responsible for formulating laws, rules & regulations. While we can’t ignore the concerns of the pharma companies facing complex issues in regulatory legal hurdles in IPR challenges, pricing &other issues related to patent regime. Pharmaleaders believe that the evolving global and domestic market dynamics are likely to result in significant opportunities and challenges for pharma companies operating in India, both Indian companies as well as Indian affiliates of MNC companies. Some key issue areas are already starting to capture the attention of leadership teams within the industry.

The highlight of the seminar was the panel discussion on “Will Innovations in India drive the next generation of global cosmetics Dermatology trends ?” where country’s top doctors & industry debated on the latest innovations in the cosmetic Dermatology field. The panellists argued that the skin care category is going to be the  the next  big business area of the sector the world over & hence the industry will have a unique opportunity to see the latest technologies in this segment, presented by companies from different countries at the forthcoming in-cosmetics also the treatment process of the Cosmetic Dermatologists. India is considered by many as a hotbed of innovation. However, innovating successfully in India is far from easy. But, as we debate Breakthrough Innovation & Path-Breaking Treatment Process, success is rooted in three core principles of Demand-driven Innovation: demand-driven insight, demand-driven development, and pervasive leadership. Noted Plastic and Cosmetic Surgeon Dr. Viral Desai, Dr Manoj Khanna,Dr. Rashmi Shetty, Dr Nilyini G, Ms. Kiren Shrivastav, of Molecule Communications were among those part of the brainstorming session.

Addressing the industry leaders & leading faces of the medical profession, Mr. Louis Banks who has often  been referred to as the Godfather of Indian Jazz & the iconic music composer was the Chief Guest of the evening conferred to top achievers of the country & urged the industry to provide affordable medicines to the common masses in india.

The Evening Award ceremony was marked by the presence of the top business leaders, Industry stalwarts, politicians, eminent healthcare leaders, medical professionals.

The award Winners are :

Social Entrepreneur of the Year 2015

Dr. Huzaifa Khorakiwala, CEO, Wockhardt Foundation

India’s Most Promising & Valuable Company 2015

Jenburkt Pharmaceuticals Limited

Change-Agent in Healthcare Innovations 2015

Adroit Biomed Ltd

Pharmaleader of the Year 2015

Mr. Prakash Kumar Guha, Managing Director, Zuventus Healthcare  Limited

India’s Most Admired Health Insurance Company of the Year 2015

Bajaj Allianz Health Insurance Company Ltd

CEO of the Year 2015

Mr. Tapan Singhel, CEO & MD, Bajaj Allianz General Insurance Company Ltd

Mr. Varun Khanna, Managing Director, Becton Dickinson India  Private Limited 

Innovative Breakthrough in Cancer Research & Patients Safety 2015

Emcure Pharmaceuticals Ltd

Emerging Company of the Year 2015

Koye Pharmaceuticals Pvt  ltd

India’s Most Watched Company of the year 2015

Akumentis Healthcare Ltd

Most Promising Expert in Regenerative Medicine 2015

Dr. Deepak Chaturvedi, Physician Endocrinologist, Diabetologist

Innovative Breakthrough in Side-Effect-Free Healthcare Solution  Provider 2015

Advanced Vital Enzymes Ltd

India’s Most Promising Hair Transplant Surgeon 2015

Dr. Viral Desai, Medical Director & Founder, DHI Hair Transplant

India’s most Admired Plastic & Cosmetic Surgeon 2015

Dr. Viral Desai, Plastic & Cosmetic Surgeon

Asia’s Most Valuable & Breakthrough Innovator in Cardio Thoracic  & Vascular Surgery 2015

Dr. Kaushal Pandey, Cardio Thoracic and Vascular Surgeon

Most Valuable & Admired Hospital 2015

Hinduja Hospital and Medical Research Centre

India’s Most Admired Medical Technology Company of the year

Becton Dickinson India Private Limited

Change-Agent in Women’s Healthcare

The Good World Foundation

India’s Most Inspiring Women Business Leader in Cosmetic  Dermatology 2015

Dr. Chytra. V. Anand, Founder & Chief Medical Director Kosmoderma

Innovative Cosmetic Dermatologist 2015

Dr . Nilayini G, Founder, Blu Skin & Cosmetology Clinic

Most Promising & Valuable Communication Agency 2015

Molecule Communications Pvt. Ltd

Physician’s First Choice as Most Valuable & Admired Pharma  Company 2015

Abbott India Limited

Most Promising Sexual Health Physician and Counselor 2015

Prof. Dr Deepak K Jumani

Emerging Brand of the Year 2015

CARIPILL

Lifetime Achievement Award

Prof R. D. Joshi

Breakthrough Innovation in Facial Plastic Surgery

Dr. Debraj Shome

Most Valuable & Admired Cosmetic Dermatologist 2015

Dr.Rinky Kapoor

India’s Most Promising & Valuable Nutrition & Wellness  Centre in Diet & Nutritional Counseling 2015

Slim Sutra Slimming and Yoga Wellness Centre

Breakthrough Innovation in Cosmetic Dermatology

Dr. Rashmi Shetty

Excellence in Clinical Pharmacology & Medico- Marketing

Dr. Dilip Pawar

Emerging Anti-Aging  & Obesity Management Pharma Company

AVI Pharma Pvt. Ltd

India’s Most Admired Hair Transplant Surgeon 2015

Dr. Manoj Khanna

Company of the year 2015

Wallace Pharmaceuticals Ltd